ACST Stock – (NASDAQ: ACST) is giving an update on the usage
As required pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or perhaps the “Company”) ACST Stock (NASDAQ: ACST – TSX V: ACST) is actually giving an update on the usage of its “at-the market” equity providing plan.
As previously disclosed, Acasti entered into an amended as well as restated ATM sales agreement on June twenty nine, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. and also H.C. Co. and Wainwright, LLC (collectively, the “Agents”), to implement an “at-the market” equity offering system under which Acasti may issue and market from time to time the everyday shares of its having an aggregate offering price of up to seventy five dolars million through the Agents (the “ATM Program”).
ACST Stock – Pursuant to the ATM Program, as necessary pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the end distributions reported on January 27, 2021, Acasti issued an aggregate of 20,159,229 common shares (the “ATM Shares”) over the NASDAQ Stock Market for aggregate yucky proceeds to the Company of US$21.7 million. The ATM Shares had been offered at prevailing market prices averaging US$1.0747 a share. No securities were offered in the facilities of the TSXV or, to the knowledge of the Company, in Canada. The ATM Shares were offered pursuant to a U.S. registration statement on Form S-3 (No. 333 239538) as made effective on July 7, 2020, as well as the Sales Agreement. Pursuant to the Sales Agreement, a cash commission of 3.0 % on the aggregate gross proceeds raised was given to the Agents in connection with their services. As a consequence of the recent ATM sales, Acasti has a total of 200,119,659 common shares issued and superb as of March five, 2021.
The additional capital raised has strengthened Acasti’s balance sheet and will supply the Company with supplemental freedom in its ongoing review process to explore and evaluate strategic options.
About Acasti – ACST Stock
Acasti is actually a biopharmaceutical innovator that has historically focused on the research, commercialization and development of prescribed drugs using OM3 greasy acids delivered both as totally free fatty acids and bound-to-phospholipid esters, created from krill oil. OM3 fatty acids have extensive clinical evidence of efficacy and safety in lowering triglycerides in people with HTG. CaPre, or hypertriglyceridemia, an OM3 phospholipid therapeutic, was being created for people with severe HTG.
Forward Looking Statements – ACST Stock
Statements of that press release which aren’t statements of historical or current fact constitute “forward looking information” to the meaning of Canadian securities laws and “forward looking statements” within the meaning of U.S. federal securities laws (collectively, “forward looking statements”). Such forward looking statements include known and unknown risks, uncertainties, as well as other unknown elements that could cause the particular outcomes of Acasti to be materially different from historical success and from any later results expressed or perhaps implied by such forward looking statements. In addition to statements which explicitly describe such risks and uncertainties, people are urged to give some thought to statements marked with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or other related expressions to be uncertain and forward-looking. People are actually cautioned not to place undue reliance on these forward looking statements, which speak simply as of the day of this particular press release. Forward-looking assertions in that press release include, but aren’t limited to, statements or info concerning Acasti’s strategy, succeeding operations and the review of its of strategic alternatives.
The forward-looking claims contained in this press release are expressly qualified in the entirety of theirs by this cautionary statement, the “Special Note Regarding Forward Looking Statements” section in Acasti’s newest annual report on Form 10-K and quarterly report on Form 10 Q, which are actually readily available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at www.sedar.com and on the investor aisle of Acasti’s site at www.acastipharma.com. Many forward looking claims in this press release exist as of the particular date of this particular press release.
ACST Stock – Acasti doesn’t undertake to redesign any such forward-looking statements whether as a consequence of info that is brand new , future events or even otherwise, except as called for by law. The forward looking assertions contained herein are also subject generally to risks and assumptions as well as uncertainties that are described from time to time in Acasti’s public securities filings with the Securities and exchange Commission and The Canadian securities commissions, including Acasti’s newest annual report on Form 10-K and quarterly report on Form 10 Q underneath the caption “Risk Factors“.
ACST Stock – (NASDAQ: ACST) is actually giving an update on the usage